Literature DB >> 2554239

Proto-oncogene amplification and human breast tumor phenotype.

J Adnane1, P Gaudray, M P Simon, J Simony-Lafontaine, P Jeanteur, C Theillet.   

Abstract

Amplification of c-myc, c-erbB-2, hst and int-2 proto-oncogenes was investigated in two independently collected breast tumor series comprising 292 carcinomas. Differences in the frequencies of amplification could be observed between these two series for c-myc (9.3% vs. 20.8%) and hst/int-2 (21.5% vs. 15.6%) whereas similar values were found for c-erbB-2 (22.5% vs. 20.3%). Statistical correlations between amplification and disease parameters were also dependent on population sampling. Therefore we performed our statistical analysis on the pooled populations and focused on the 219 primary breast carcinomas from patients without therapy prior to surgery. Amplification of c-erbB-2 was strongly correlated to the absence of either estrogen (ER-, P = 0.003) or progesterone (PR-, P = 0.004) receptors. An amplified c-myc was significantly associated with PR- (P = 0.005) and was prevalent in high grade tumors. On the contrary, hst/int-2 amplification was correlated to PR+ tumors (P = 0.01) and was more frequent in ER+ and low grade tumors, and was also correlated with lymph node involvement (P = 0.04). Our data suggest that amplification of each of these proto-oncogenes could be representative of a particular subset of breast tumors. Therefore, proto-oncogene amplification may be helpful in characterizing new biological subclasses in human breast cancer.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2554239

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  29 in total

1.  Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4.

Authors:  E Neuman; M H Ladha; N Lin; T M Upton; S J Miller; J DiRenzo; R G Pestell; P W Hinds; S F Dowdy; M Brown; M E Ewen
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

2.  Breast biopsy nuclear pellets are a convenient source of DNA for routine determination of Her-2/neu gene amplification.

Authors:  O Malka; Y Pollack; D Benharroch; Y Cohen; R Levy; I Yanai-Inbar; J Gopas
Journal:  Breast Cancer Res Treat       Date:  1991-09       Impact factor: 4.872

3.  Biological indices in the assessment of breast cancer.

Authors:  A S Leong; A K Lee
Journal:  Clin Mol Pathol       Date:  1995-10

4.  Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution.

Authors:  M D Planas-Silva; R A Weinberg
Journal:  Mol Cell Biol       Date:  1997-07       Impact factor: 4.272

5.  C-myc as a predictive marker for chemotherapy in metastatic breast cancer.

Authors:  Nataša Todorović-Raković; Zora Nešković-Konstantinović; Dragica Nikolić-Vukosavljević
Journal:  Clin Exp Med       Date:  2011-11-24       Impact factor: 3.984

6.  Chromosomal sites for hepatitis B virus integration in human hepatocellular carcinoma.

Authors:  T Tokino; K Matsubara
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

7.  c-myc reverses neu-induced transformed morphology by transcriptional repression.

Authors:  T C Suen; M C Hung
Journal:  Mol Cell Biol       Date:  1991-01       Impact factor: 4.272

8.  ErbB-2 oncoprotein overexpression in breast carcinoma: inverse correlation with biochemically- and immunohistochemically-determined hormone receptors.

Authors:  A A Keshgegian
Journal:  Breast Cancer Res Treat       Date:  1995-08       Impact factor: 4.872

Review 9.  Cyclin D1 and human neoplasia.

Authors:  R Donnellan; R Chetty
Journal:  Mol Pathol       Date:  1998-02

10.  Prognostic value of c-erbB-2 expression in uterine cervical carcinoma.

Authors:  R J Hale; C H Buckley; H Fox; J Williams
Journal:  J Clin Pathol       Date:  1992-07       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.